Aiforia vs Primaa
Both are CE marked algorithm vendors with no FDA clearance and an A on AI centrality, but they diverge on maturity and specialty. If you want broad, already adopted multi tumor coverage with published deployment, start with Aiforia. If you need dermatopathology specifically, where almost nothing else exists, or you want algorithms that run across four host platforms with minimal lock in, start with Primaa, accepting thinner published evidence. Aiforia spans five tumor types plus lymph node with named clinical deployments and a model building engine. Primaa is narrower, covering breast and skin, but its Cleo Skin is described as the first CE-IVDR tool in dermatopathology, and its algorithms run inside four separately available platforms, which lowers the risk of being locked to one workspace.
- Breadth and adoption: CE-IVD suites across five tumor types plus lymph node, with named clinical deployments at AP-HP, Nantes, Institut Curie, and a Lombardy regional selection, a deeper adoption record than Primaa, whose validation studies were still pending at review.
- A model building engine via Aiforia Create.
- Vendor stability visibility from its Helsinki listing.
- Dermatopathology coverage almost nothing else here offers: Cleo Skin is described as the first CE-IVDR tool in that specialty, a genuinely underserved area rather than the crowded breast application.
- The clearest multi platform integration of any algorithm only vendor in the index: Cleo runs inside AISight, Proscia, PathPresenter, and Gestalt, three of them separately indexed, which lowers platform lock in.
- An assistive posture measured as such: its dermatopathology validation was designed to compare pathologist performance with and without the AI, treating the human and machine pairing as the unit of evaluation.
Side-by-Side
| Axis | A Aiforia |
P Primaa |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both are CE-IVD only with no FDA clearance, and neither publishes pricing, a security attestation, or subgroup performance. Primaa is the thinner evidenced of the two: its Cleo Breast and Cleo Skin validation studies were still underway and unpublished at review, so its clinical evidence and model transparency grade below Aiforia's. The dermatopathology gap matters because skin AI carries a well documented performance concern across skin tones, and Primaa has published no subgroup analysis against it. One scope caveat: Cleo Skin's regulatory status varies by route, listed as CE-IVDR in some contexts and research use only in the AISight integration, so a buyer must confirm which applies to their market. Aiforia's efficiency figures are vendor quoted and not independently verified, and its integration is asserted through partnerships rather than enumerated.